Newbridge Financial Services Group
MBRX icon

Newbridge Financial Services Group’s Moleculin Biotech MBRX Stock Holding History

Newbridge Financial Services Group’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$57 Hold
6
– – ﹤0.01% 1274
2026
Q2 		$318 Hold
6
– – ﹤0.01% 1170
2026
Q1 		$261 Hold
6
– – ﹤0.01% 1122
2025
Q4 		$377 Hold
6
– – ﹤0.01% 1121
2025
Q3 		$1.52K Hold
6
– – ﹤0.01% 1156
2025
Q2 		$866 Buy
6
+3
+100% +$1.23K ﹤0.01% 1214
2025
Q1 		$1.33K Hold
3
– – ﹤0.01% 924
2024
Q4 		$2.32K Hold
3
– – ﹤0.01% 952
2024
Q3 		$3.88K Hold
3
– – ﹤0.01% 524
2024
Q2 		$4.81K Buy
3
+2
+200% +$4.62K ﹤0.01% 853
2024
Q1 		$4.05K Buy
+1
New +$4.26K ﹤0.01% 915

Other funds holding MBRX

Jane Street
Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
Danske Bank
Danske Bank Copenhagen K, Denmark $50.1B AUM 35.17% 1-Year Est. Return

Newbridge Financial Services Group's MBRX Position: Q3 2026 in Review

Newbridge Financial Services Group held its Moleculin Biotech (MBRX) position steady in Q3 2026 at 6 shares worth $57. The position accounts for ﹤0.01% of the portfolio, ranked #1274.

Newbridge Financial Services Group first reported a position in MBRX in Q1 2024 and has held it in 11 quarters since. The position peaked at $4.81K in Q2 2024. 5 funds tracked by Wall St. Rank hold MBRX as of Q3 2026.

  • Newbridge Financial Services Group held 6 shares of Moleculin Biotech worth $57 as of Q3 2026.
  • Newbridge Financial Services Group left its Moleculin Biotech share count unchanged in Q3 2026.
  • Moleculin Biotech made up ﹤0.01% of Newbridge Financial Services Group's portfolio in Q3 2026, its #1274 holding.
  • Newbridge Financial Services Group first reported a position in Moleculin Biotech in Q1 2024 and has held it in 11 quarters since.
  • Newbridge Financial Services Group's Moleculin Biotech position peaked at $4.81K in Q2 2024.
  • 5 funds tracked by Wall St. Rank held Moleculin Biotech as of Q3 2026.

Based on Newbridge Financial Services Group's 13F filing for Q3 2026, filed 15 Oct 2026.